Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
500.00    12.60 (2.59%)
Bid:
500.00
Ask:
501.00
Spread: 1.00 (0.20%)
Market Cap: £1.35b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

CONTRACT AWARDS

2 Jul 2018 07:00

RNS Number : 1647T
Chemring Group PLC
02 July 2018
 

FOR IMMEDIATE RELEASE 2 JULY 2018

 

CHEMRING GROUP PLC ("Chemring", the "Group" or the "Company")

 

 

CONTRACT AWARDS

 

 

Chemring Group is pleased to announce that its US based subsidiary, Chemring Countermeasures USA ("CCM USA"), has been awarded two contracts totalling approximately $42 million.

 

The first contract, which is for the manufacture and delivery of M206 and MJU-7A/B infrared decoys for the US Army and Air Force, is valued at approximately $32 million, and was awarded under CCM USA's current 5-year Indefinite Delivery Indefinite Quantity ("IDIQ") contract with the US Army Garrison at Rock Island Arsenal. Deliveries under this contract will be made between 2018 and 2019, with all work to be performed at CCM USA's facility in Toone, Tennessee. 

 

The second contract, which is for the manufacture and delivery of MJU-66 Special Material Decoys for the US Air Force, is valued at approximately $10 million and is the second award under the $29 million IDIQ that was announced in August 2017. Deliveries under this contract will be made in 2019, with all work to be performed at CCM USA's facility in Chester Township, Pennsylvania. 

 

Michael Ord, Group Chief Executive of Chemring, commented:

 

"These contracts demonstrate the continued confidence of the US Army and Air Force in Chemring's ability to develop and supply quality aircraft countermeasures, and it reinforces the Group's decision to invest in the transformation project at our Tennessee facility.

 

"These contracts complete the required FY18 order intake in our Countermeasures segment, provide a strong platform for FY19, and are further evidence of the recovery, and our strengthening position, in the global countermeasures market."

 

-ENDS-

 

For further information:

 

Rupert Pittman Group Director of Corporate Affairs, 01794 833901

Chemring Group PLC

 

Andrew Jaques MHP Communications 020 3128 8100

James White

 

 

Notes to editors

· Chemring is a global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

· Employing approximately 2,600 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under three strategic product segments: Countermeasures, Sensors, and Energetics

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.co.uk

 

Cautionary statements

This announcement contains unaudited information based on management accounts and forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements.

 

There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are; increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects.

 

Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

No statement in this announcement is intended as a profit forecast for FY18 and no statement in this announcement should be interpreted to mean that underlying operating profit for the current or future financial years would necessarily be above a minimum level, or match or exceed the historical published underlying operating profit or set a minimum level of underlying operating profit.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRASSUEFFFASESW
Date   Source Headline
17th Aug 20237:00 amRNSTransaction in Own Shares
16th Aug 20237:00 amRNSTransaction in Own Shares
15th Aug 20237:00 amRNSTransaction in Own Shares
14th Aug 20237:00 amRNSTransaction in Own Shares
11th Aug 20237:00 amRNSTransaction in Own Shares
10th Aug 20237:00 amRNSTransaction in Own Shares
8th Aug 20237:00 amRNSUpdate on appointment of Chief Financial Officer
8th Aug 20237:00 amRNSTransaction in Own Shares
7th Aug 20237:00 amRNSTransaction in Own Shares
4th Aug 20234:16 pmRNSDirector/PDMR Shareholding
4th Aug 20234:15 pmRNSDirector/PDMR Shareholding
4th Aug 20237:00 amRNSTransaction in Own Shares
3rd Aug 20237:00 amRNSTransaction in Own Shares
2nd Aug 20237:00 amRNSTransaction in Own Shares
1st Aug 20239:26 amRNSTotal Voting Rights
1st Aug 20237:00 amRNSShare buyback programme
3rd Jul 20237:00 amRNSDirector/PDMR Shareholding
21st Jun 20239:47 amRNSBlock listing Interim Review
13th Jun 20237:00 amRNSAppointment of non-executive director
6th Jun 20237:00 amRNSHalf year results to 30 April 2023
1st Jun 202310:28 amRNSTotal Voting Rights
24th May 20237:00 amRNSAppointment of Chief Financial Officer
2nd May 20232:51 pmRNSTotal Voting Rights
20th Apr 202312:02 pmRNSDirector Declaration
3rd Apr 20239:25 amRNSTotal Voting Rights
29th Mar 20237:00 amRNSContract Award
28th Mar 20233:29 pmRNSHolding(s) in Company
16th Mar 20234:23 pmRNSDoc re. Ordinary & Special Resolutions
15th Mar 20233:11 pmRNSResult of AGM
15th Mar 20237:00 amRNSAGM Trading Update
1st Mar 202310:33 amRNSTotal Voting Rights
24th Feb 20239:07 amRNSDirector Declaration
1st Feb 202310:10 amRNSTotal Voting Rights
24th Jan 20233:09 pmRNSDirector/PDMR Shareholding
23rd Jan 20237:00 amRNSDirectorate Change
16th Jan 202310:44 amRNSNotice of AGM
9th Jan 20237:10 amRNSDirector Declaration
3rd Jan 202310:54 amRNSTotal Voting Rights
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
19th Dec 20223:41 pmRNSBlock listing Interim Review
14th Dec 202212:31 pmRNSDirector/PDMR Shareholding
14th Dec 202212:28 pmRNSDirector/PDMR Shareholding
14th Dec 202212:27 pmRNSDirector/PDMR Shareholding
14th Dec 202212:25 pmRNSDirector/PDMR Shareholding
14th Dec 202212:23 pmRNSDirector/PDMR Shareholding
14th Dec 202212:20 pmRNSDirector/PDMR Shareholding
13th Dec 20227:00 amRNSFinal Results
1st Dec 202210:01 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.